English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, October 22, 2018
エーザイとMSD、日本で「レンビマ」(レンバチニブ)の情報提供における協業を開始
Friday, October 19, 2018
Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
慶應大とエーザイ、iPS細胞を用いたパーキンソン病に対する治療薬候補物質を発見
Thursday, October 18, 2018
エーザイ、第11回アルツハイマー病臨床試験会議(CTAD)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference
Wednesday, October 17, 2018
エーザイとPurdue Pharma、「レンボレキサント」の不眠障害を対象とした2つめのピボタル臨床第III相試験(SUNRISE 2試験)において良好なトップライン結果を取得
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Tuesday, October 16, 2018
エーザイ、肥満症治療剤lorcaserin Eurofarmaとラテンアメリカにおける提携契約を締結
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma
Friday, October 12, 2018
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575